We are live on ! Find out more
CRL icon

Charles River Laboratories

676 hedge funds and large institutions have $14.1B invested in Charles River Laboratories in 2024 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 257 increasing their positions, 229 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 46

88% more funds holding in top 10

Funds holding in top 10: 815 (+7)

14% more capital invested

Capital invested by funds: $12.4B → $14.1B (+$1.75B)

12% more repeat investments, than reductions

Existing positions increased: 257 | Existing positions reduced: 229

7% more funds holding

Funds holding: 633676 (+43)

0.47% less ownership

Funds ownership: 102.25%101.79% (-0.47%)

47% less call options, than puts

Call options by funds: $52M | Put options by funds: $98.3M

Holders
676
Holders Change
+43
Holders Change %
+6.79%
% of All Funds
9.74%
Holding in Top 10
15
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+87.5%
% of All Funds
0.22%
New
92
Increased
257
Reduced
229
Closed
46
Calls
$52M
Puts
$98.3M
Net Calls
-$46.4M
Net Calls Change
-$20.6M
Name Holding Trade Value Shares
Change
Change in
Stake
KeyBank National Association
326
KeyBank National Association
Ohio
$1.29M -$24.4K -102 -2%
MA
327
MJP Associates
Connecticut
$1.28M +$86.2K +361 +8%
Wealth Enhancement Advisory Services
328
Wealth Enhancement Advisory Services
Minnesota
$1.24M -$8.84K -37 -0.8%
Creative Planning
329
Creative Planning
Kansas
$1.23M +$73.8K +309 +7%
DBIA
330
Dumont & Blake Investment Advisors
New Jersey
$1.2M +$14.8K +62 +1%
OPERF
331
Oregon Public Employees Retirement Fund
Oregon
$1.19M +$96.2K +403 +10%
Nordea Investment Management
332
Nordea Investment Management
Sweden
$1.19M
PAM
333
Panagora Asset Management
Massachusetts
$1.18M
AG
334
AlTi Global
New York
$1.18M +$955 +4 +0.1%
GLA
335
Great Lakes Advisors
Illinois
$1.18M -$83.3K -349 -7%
FFA
336
Fortune Financial Advisors
Kansas
$1.17M
ETC
337
Exchange Traded Concepts
Oklahoma
$1.17M -$275K -1,152 -21%
PS
338
Principal Securities
Iowa
$1.17M +$261K +1,091 +34%
SMDAM
339
Sumitomo Mitsui DS Asset Management
Japan
$1.16M +$11K +46 +1%
GIBU
340
Gulf International Bank (UK)
United Kingdom
$1.16M +$7.88K +33 +0.8%
TRSOTSOK
341
Teachers Retirement System of the State of Kentucky
Kentucky
$1.13M -$51.8K -217 -5%
Allianz Asset Management
342
Allianz Asset Management
Germany
$1.11M +$80.7K +338 +9%
LA
343
LBP AM
France
$1.1M +$461K +1,929 +90%
BBVA
344
Banco Bilbao Vizcaya Argentaria
Spain
$1.09M +$346K +1,449 +56%
UM
345
UniSuper Management
Australia
$1.08M +$783K +3,278 +452%
LIM
346
Leavell Investment Management
Alabama
$1.08M -$143K -600 -13%
Pathstone Holdings
347
Pathstone Holdings
New Jersey
$1.08M -$212K -889 -18%
N
348
Natixis
France
$1.06M +$933K +3,905 New
KRS
349
Kentucky Retirement Systems
Kentucky
$1.06M -$49.7K -208 -5%
PAS
350
Park Avenue Securities
New York
$1.03M +$48.5K +203 +6%

CRL Hedge Fund Activity: Q1 2024 in Review

676 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2024, worth a combined $14.1B — up 14% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new CRL positions and 46 closed out — a net gain of 46 holders — while 257 added to existing stakes and 229 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $158M. The largest seller was Morgan Stanley, cutting an estimated $122M.

  • 676 institutional investors held Charles River Laboratories (CRL) as of Q1 2024, up from 633 in Q4 2023.
  • Funds reported $14.1B of Charles River Laboratories stock for Q1 2024, up 14% quarter-over-quarter.
  • 92 funds opened new Charles River Laboratories positions in Q1 2024 and 46 closed out, a net change of +46 holders.
  • The largest Charles River Laboratories buyer in Q1 2024 was Marshall Wace, an estimated $158M added.
  • The largest Charles River Laboratories seller in Q1 2024 was Morgan Stanley, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2024.